Physician profile
Mark B Mccormick
NPI 1750395760
$3,317.18
in general payments reported to CMS, 2019-2025
28 companies · $457 in 2025
The $457 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $596 · 2021: $424 · 2022: $387 · 2023: $446 · 2024: $518 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.83 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $622.64 | 2019-2023 | |
| Astellas Pharma US INC | $429.54 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $322.16 | 2019-2022 | |
| Pfizer INC. | $306.92 | 2019-2024 | |
| Exact Sciences Corporation | $173.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $161.84 | 2021-2024 | |
| Allergan, INC. | $143.23 | 2019-2020 | |
| Coopersurgical, INC. | $122.25 | 2020-2024 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $108.04 | 2023-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $101.36 | 2019-2025 | |
| Agile Therapeutics, INC. | $89.99 | 2021-2023 | Twirla |
| Millicent US INC | $89.72 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Hologic Sales and Service, LLC | $79.51 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Exeltis, USA INC. | $69.16 | 2021-2025 | Slynd |
| Avion Pharmaceuticals | $68.57 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $65.59 | 2022 | |
| Biogen, INC. | $59.19 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $58.39 | 2019 | |
| Myovant Sciences INC. | $52.66 | 2021-2022 | |
| Roche Diagnostics Corporation | $36.78 | 2019 | |
| Amag Pharmaceuticals, INC. | $31.61 | 2019 | |
| Sanofi Pasteur INC. | $26.30 | 2024 | |
| Shield Therapeutics INC | $23.81 | 2023 | Accrufer |
| Ibsa Pharma INC. | $21.64 | 2023 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2023 | Seglentis |
| Duchesnay USA Incorporated | $13.77 | 2019 | |
| Channel Medsystems, INC. | $12.04 | 2025 | |
| Lupin INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.